MedTrace Logo

Vonoprazan for Helicobacter Pylori Eradication in Adolescents

NCT06162949 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2024-08-28

No results posted yet for this study

Summary

The trial tends to evaluate the efficacy of vonoprazan-based triple therapy in eradicating H. Pylori infection in adolescent patients in Egypt, in comparison to standard treatment regimens to determine if it offers superior eradication rates (VONTAPE trial).

Conditions

  • Treatment Effectiveness

Interventions

DRUG

Vonoprazan

an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.

DRUG

Amoxicillin

An antibiotic of penicillins antibiotic group

DRUG

Clarithromycin

An antibiotic of macrolide group

DRUG

Esomeprazole

An acid suppressor therapy that blocks the proton pump.

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Sameh A Lashen, MD · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-08-01
Completion
2024-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06162949 on ClinicalTrials.gov